OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Narendra Chirmule, PhD, is CEO at SymphonyTech Biologics.
A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis
Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.
Advances in preclinical development play a crucial role in reducing cost for developing biosimilars.